Patent · US Active

Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment

US9896730B2 · kind B2 · utility

3Cited by

13References

16Claims

0Family size

Assignees

OSI Pharmaceuticals, LLC · US
AVEO Pharmaceuticals, Inc. · US

Inventors

Julie Kan · San Diego, US
Stuart Thomson · Farmingdale, US
Gretchen M. Argast · Farmingdale, US
Matthew E. O'Connor · Massapequa Park, US
Murray Robinson · Malibu, US
Bin Feng · Beijing, CN
Joerg Heyer · Cambridge, US
Maria Isabel Chiu · Boston, US
Richard Nicoletti · Lanesborough, US

Key dates

Filing date	Apr 25, 2012
Grant date	Feb 20, 2018
Priority date	—
Expiry date	Apr 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.